Vistagen Therapeutics Inc (VTGN)

$0.73 +0.01 (2.08%)
Market Cap 28.16M
Revenue (ttm) 490,000.00
Net Income (ttm) -51.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,493.88%
Debt to Equity Ratio 0.00
Volume 1,772,500
Avg Vol 2,715,120
Day's Range N/A - N/A
Shares Out 39.50M
Stochastic %K 1%
Beta 0.56
Analysts Hold
Price Target $0.95

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 577 3600
Address:
343 Allerton Avenue, South San Francisco, United States
MoneyGroupLLC
MoneyGroupLLC Dec. 25 at 4:38 PM
Enter: $VTGN Calls Strike Price: $1 Expiry Date: JAN 16 2026 Buy in Price: $0.03 - $0.05 Sell Price: $0.05 Profit : +51% (Turn every $1 into $1.51) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
apocalypse6x6
apocalypse6x6 Dec. 25 at 2:12 PM
$VTGN merry Christmas everyone
0 · Reply
seppi
seppi Dec. 24 at 5:49 PM
$VTGN same story. Good start, bad close
0 · Reply
Bangerplays
Bangerplays Dec. 24 at 5:09 PM
$VTGN nice starter here
0 · Reply
mark31
mark31 Dec. 24 at 3:50 PM
$VTGN
0 · Reply
ACInvestorBlog
ACInvestorBlog Dec. 24 at 3:43 PM
$VTGN is today the day ? I reafirm what i have been saying... This stock is trading at bargain prices , net cash is $1.56 per share. 👉ADX Bullish crossover 📈
0 · Reply
Bran0723
Bran0723 Dec. 24 at 3:26 PM
$VTGN
0 · Reply
mark31
mark31 Dec. 24 at 3:23 PM
$VTGN
0 · Reply
Jackreacher12
Jackreacher12 Dec. 24 at 3:22 PM
$VTGN LET’S TAKE IT TO THE 1$
0 · Reply
To_De_Moon
To_De_Moon Dec. 24 at 3:18 PM
$VTGN
0 · Reply
Latest News on VTGN
Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Dec 17, 2025, 12:42 PM EST - 7 days ago

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Dec 17, 2025, 8:30 AM EST - 8 days ago

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Nick Tressler as Chief Financial Officer

Dec 1, 2025, 8:30 AM EST - 24 days ago

Vistagen Appoints Nick Tressler as Chief Financial Officer

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Nov 26, 2025, 8:30 AM EST - 4 weeks ago

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026

Nov 18, 2025, 7:45 AM EST - 5 weeks ago

Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026

Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 7:01 PM EST - 5 weeks ago

Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Nov 13, 2025, 4:30 PM EST - 5 weeks ago

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Nov 10, 2025, 8:30 AM EST - 6 weeks ago

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Vistagen to Participate in Stifel Healthcare Conference 2025

Nov 5, 2025, 8:30 AM EST - 7 weeks ago

Vistagen to Participate in Stifel Healthcare Conference 2025

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Nov 3, 2025, 8:30 AM EST - 7 weeks ago

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Paul Edick to its Board of Directors

Oct 29, 2025, 8:30 AM EDT - 2 months ago

Vistagen Appoints Paul Edick to its Board of Directors

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Oct 16, 2025, 8:30 AM EDT - 2 months ago

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 9, 2025, 8:30 AM EDT - 3 months ago

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

Aug 8, 2025, 2:13 PM EDT - 4 months ago

Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Aug 7, 2025, 4:30 PM EDT - 4 months ago

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Jul 31, 2025, 8:30 AM EDT - 5 months ago

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 5 months ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Jul 15, 2025, 8:30 AM EDT - 5 months ago

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Jun 25, 2025, 8:30 AM EDT - 6 months ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

Jun 17, 2025, 6:49 PM EDT - 6 months ago

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Jun 17, 2025, 4:30 PM EDT - 6 months ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Jun 12, 2025, 8:30 AM EDT - 7 months ago

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Jun 2, 2025, 8:30 AM EDT - 7 months ago

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

May 28, 2025, 8:30 AM EDT - 7 months ago

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

May 23, 2025, 8:30 AM EDT - 7 months ago

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Apr 17, 2025, 8:30 AM EDT - 9 months ago

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Mar 19, 2025, 8:30 AM EDT - 10 months ago

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Mar 4, 2025, 8:30 AM EST - 10 months ago

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Feb 20, 2025, 8:30 AM EST - 11 months ago

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

Feb 14, 2025, 6:19 PM EST - 11 months ago

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript

Feb 13, 2025, 8:47 PM EST - 11 months ago

Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Feb 13, 2025, 4:30 PM EST - 11 months ago

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Feb 6, 2025, 8:30 AM EST - 11 months ago

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Feb 5, 2025, 8:30 AM EST - 11 months ago

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Jan 14, 2025, 8:30 AM EST - 1 year ago

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Jan 10, 2025, 8:30 AM EST - 1 year ago

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Vistagen to Present at the Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:30 AM EST - 1 year ago

Vistagen to Present at the Stifel 2024 Healthcare Conference

Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript

Nov 10, 2024, 7:43 AM EST - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Nov 7, 2024, 4:20 PM EST - 1 year ago

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Vistagen to Present at the 2024 Neuroscience Education Institute Congress

Nov 5, 2024, 8:30 AM EST - 1 year ago

Vistagen to Present at the 2024 Neuroscience Education Institute Congress

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder

Oct 15, 2024, 7:25 AM EDT - 1 year ago

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

Oct 9, 2024, 8:30 AM EDT - 1 year ago

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Sep 23, 2024, 8:30 AM EDT - 1 year ago

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript

Aug 13, 2024, 7:05 PM EDT - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

Aug 13, 2024, 4:21 PM EDT - 1 year ago

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

Aug 6, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

Jul 9, 2024, 8:30 AM EDT - 1 year ago

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript

Jun 11, 2024, 6:41 PM EDT - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript

MoneyGroupLLC
MoneyGroupLLC Dec. 25 at 4:38 PM
Enter: $VTGN Calls Strike Price: $1 Expiry Date: JAN 16 2026 Buy in Price: $0.03 - $0.05 Sell Price: $0.05 Profit : +51% (Turn every $1 into $1.51) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
apocalypse6x6
apocalypse6x6 Dec. 25 at 2:12 PM
$VTGN merry Christmas everyone
0 · Reply
seppi
seppi Dec. 24 at 5:49 PM
$VTGN same story. Good start, bad close
0 · Reply
Bangerplays
Bangerplays Dec. 24 at 5:09 PM
$VTGN nice starter here
0 · Reply
mark31
mark31 Dec. 24 at 3:50 PM
$VTGN
0 · Reply
ACInvestorBlog
ACInvestorBlog Dec. 24 at 3:43 PM
$VTGN is today the day ? I reafirm what i have been saying... This stock is trading at bargain prices , net cash is $1.56 per share. 👉ADX Bullish crossover 📈
0 · Reply
Bran0723
Bran0723 Dec. 24 at 3:26 PM
$VTGN
0 · Reply
mark31
mark31 Dec. 24 at 3:23 PM
$VTGN
0 · Reply
Jackreacher12
Jackreacher12 Dec. 24 at 3:22 PM
$VTGN LET’S TAKE IT TO THE 1$
0 · Reply
To_De_Moon
To_De_Moon Dec. 24 at 3:18 PM
$VTGN
0 · Reply
Chessdoc
Chessdoc Dec. 24 at 3:17 PM
$VTGN I’m going to call it – – probably absolute bottom!
0 · Reply
Mamatrader3
Mamatrader3 Dec. 24 at 3:16 PM
$VTGN take her up I’ve got time
0 · Reply
Chessdoc
Chessdoc Dec. 24 at 3:06 PM
$VTGN Their portfolio and patents are worth a hell of a lot more than the current SP would reflect! Starting a major position here.
0 · Reply
mark31
mark31 Dec. 24 at 3:06 PM
$VTGN time to move
0 · Reply
ParabolicalSpartan
ParabolicalSpartan Dec. 24 at 3:04 PM
What is happening to ticker UPC ?! Looks like they are SQUEEZING ticker UPC up next UPC is breaking out like crazy.. Only 500k float. All eyes on UPC now it seems -- $PSKY $VTGN $OCGN $COEP --
0 · Reply
Icansee
Icansee Dec. 24 at 3:04 PM
$VTGN
0 · Reply
nightstocker15
nightstocker15 Dec. 24 at 3:03 PM
$VTGN let’s go 🙌
0 · Reply
Chessdoc
Chessdoc Dec. 24 at 2:38 PM
$VTGN Probably Singh some last-minute tax loss selling
0 · Reply
Bobby_J_Bomb
Bobby_J_Bomb Dec. 24 at 2:29 PM
$VTGN looks like going to retest 0.68 low. If it doesn't hold, how low will it go. What a disaster.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 6:48 AM
Enter: $VTGN Calls Strike Price: $1 Expiry Date: JAN 16 2026 Buy in Price: $0.03 - $0.03 Sell Price: $0.06 Profit : +94% (Turn every $1 into $1.94) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
mb0157
mb0157 Dec. 24 at 1:16 AM
$VTGN. Starting to piece this all together. Vistagen maybe already in talks with Bespak if not already working with them. If I was a betting man, which I am. I’d say Bayer is the third piece to this for PH 80 license deal. And jpm is where I anticipate the deal may be announced.
1 · Reply
Icemanrush16
Icemanrush16 Dec. 24 at 12:46 AM
$VTGN 🫢
0 · Reply